Health Kick Podcast: Commercialising orphan drugs, the need for better regulation and the ASX’s lifestyle play problem
Health & Biotech
share
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.
In this episode Tim chats with Race Oncology (ASX:RAC) CEO Peter Molloy and executive director and CSO Daniel Tillett.
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field.
The company’s key asset is a chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s.
Race has now rediscovered Bisantrene, been granted two patents and secured Orphan Drug designation and Rare Paediatric Disease designation.
So tune in to hear the trio discuss commercialising orphan drugs, the need for better biotech regulation and the ASX’s lifestyle play problems.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!
